Questions for an offer that leaves gaps

What does compounded mean here?

Compounding means a pharmacist, physician or registered facility prepares a medicine rather than supplying a finished approved product.

A compounded preparation reaches patients without FDA approval or the agency’s prior check of safety, quality and effectiveness.

That is the federal position recorded in September 2026, not a claim that all compounding is unlawful.

Ask what need calls for compounding rather than an approved medicine, then request the name of the pharmacy making it.

Did the shortage leave an open route?

FDA said the tirzepatide shortage was over on 19 December 2024. This decision was checked for the September 2026 notes.

During the shortage, FDA had temporarily held off taking action over certain rule breaches tied to making copies of tirzepatide. That delay ended on 18 February 2025 for ordinary compounding pharmacies. For larger registered makers, called outsourcing facilities, it ended on 19 March 2025.

An outsourcing facility registers with FDA and prepares batches of sterile, or germ-free, medicines, often used in hospitals and clinics.

The September 2026 check found tirzepatide absent from the national shortage list.

Local stock problems and FDA’s national shortage listing are separate questions.

Can a personal change make a difference?

Under the federal rules checked in September 2026, an ordinary compounding pharmacy cannot routinely make, or make excessive amounts of, a medicine that is essentially a copy of one already sold. A registered outsourcing facility has a separate rule against making a medicine that is essentially a copy of an approved drug.

An ordinary compounding pharmacy may fall within an exception to the copy rule. For that to apply, the prescriber must decide that the changed version differs in a significant way for the named patient. The law then leaves that version out of its definition of a copy.

That exception does not follow from a lower price alone.

Ask what specific change matters for you and why. A general phrase about custom care does not explain the proposed preparation.

Does a research label change the answer?

FDA’s September 2026 advice flags research-labelled tirzepatide offered for human use: the contents have unknown quality and may be harmful.

The words “research use only” are not a substitute for a care conversation. Ask whether the offer is for an approved product or a compounded preparation, and follow the answer to its source.

What answer would close the gap?

Ask for the exact product, the prescriber, the pharmacy, the reason for the choice and the total cost. Ask who can answer a question after the medicine arrives. Keep any unanswered point visible in your notes.